[Riyadh] August 1, 2024 – Novo Genomics, a leading Saudi biotechnology company, and ZOTZ|KLIMAS, a renowned German medical laboratory, are excited to announce a strategic partnership. Facilitated by FJX, this collaboration aims to advance healthcare, biotechnology, genomics, and multi-omics in Saudi Arabia.

‍

A Visionary Partnership

In line with Saudi Arabia’s Vision 2030, which emphasizes the development of a diversified and sustainable economy, this partnership will leverage the expertise and technological prowess of both Novo Genomics and ZOTZ|KLIMAS. The collaboration seeks to foster innovation, enhance local capabilities, and establish Saudi Arabia as a regional hub for advanced diagnostics, biotechnological research and applications.

‍

“Our collaboration with ZOTZ|KLIMAS marks a significant milestone in our mission to advance biotechnological innovation in Saudi Arabia. By combining our local insights with ZOTZ|KLIMAS’ international expertise, we are poised to make substantial contributions to the global healthcare community”, states Dr. Abdulelah Alhawsawi, CEO of Novo Genomics.

‍

Advancing Genomics and Multi-Omics

The partnership will concentrate on genomics and multi-omics, which encompass various disciplines such as genomics, proteomics, metabolomics, and transcriptomics. These fields are crucial for understanding complex biological systems and developing personalized medical solutions. The joint efforts will include:

‍

• Localization: Establishing state-of-the-art diagnostic and biotech facilities in Saudi Arabia to produce and analyze genomic and multi-omics data locally, boosting the local content and reducing reliance on international resources.

• Capacity Building: Training and development programs to enhance the skills of Saudi scientists and researchers in advanced diagnostic and biotechnological techniques.

• Research and Development: Conducting cutting-edge research to discover new biomarkers, therapeutic targets, and diagnostic tools.

• Collaborative Projects: Launching joint projects that address region-specific health challenges, leveraging the unique strengths of both organizations.

‍

‍

“We are excited to partner with Novo Genomics and contribute to the growth of the healthcare sector in Saudi Arabia. Our combined efforts will not only accelerate scientific discoveries but also improve healthcare outcomes by tailoring medical solutions to the specific needs of the population”, comments Mr. Philip Graul, CEO of ZOTZ|KLIMAS.

‍

Enhancing Healthcare and Economic Growth

The partnership is expected to have a profound impact on both healthcare and economic development in Saudi Arabia. By fostering local talent and infrastructure, the collaboration will drive the growth of a knowledge-based economy, creating high-value jobs and attracting further investment into the region.

‍

Key initiatives will include:

‍

• ‍Healthcare Innovations: Developing new diagnostic and therapeutic solutions that improve patient care and health outcomes.

• Boosting Knowledge–Based Economy: Contributing to the diversification of the Saudi economy by establishing a robust biotechnology sector.

• Global Competitiveness: Positioning Saudi Arabia as a competitive player in the global biotechnology and healthcare industries.

‍

A Commitment to Excellence

Novo Genomics and ZOTZ|KLIMAS are committed to maintaining the highest standards of scientific excellence and ethical practices throughout their partnership. Both organizations will work closely with regulatory bodies, R&D authorities, academic institutions, and industry stakeholders to ensure that their initiatives align with international best practices and contribute positively to society.

‍

"Saudi Arabia’s visionary government drives innovation, creating an ideal environment for commercial success. Novo Genomics and ZOTZ|KLIMAS share a vision of genomics contributing to a healthier future and are committed to achieving it together", says Florian Jansen, CEO of FJX.  

‍

‍

‍

‍

‍

About Novo Genomics

Novo Genomics is a leading Saudi biotech company focused on genomics and multi-omics technologies to promote health and wellness in Saudi Arabia. With a focus on innovation, research, and development, Novo Genomics provides cutting-edge solutions tailored to the region.

‍

About ZOTZ|KLIMAS

ZOTZ|KLIMAS is one of Germany’s leading providers of interdisciplinary medical laboratory diagnostics, committed to improving healthcare outcomes through innovative research and collaboration. The company’s extensive network ensures accessibility and convenience for its partners, patients, and healthcare professionals.

‍

About FJX

FJX is an international advisory firm providing practical insights and solutions for strategic and operational challenges. Specializing in the GCC, CIS, and Europe, FJX supports global businesses in establishing a presence in new growth markets.

‍

Media Contacts:

For Novo Genomics: CEO, Dr. Abdulelah Alhawsawi, Email: a.alhawsawi@novo-genomics.com

For ZOTZ|KLIMAS: CEO, Mr. Philip Graul, Email: graul@zotzklimas.de

For FJX: Director Communications, Inka Kiwit, Email: inka.kiwit@thefjx.com

‍